The Role of Automatic Chemiluminescence Immunoassay Analyzer iA1000 in Tumor Testing

Tumor markers are substances cancer cells produce in response to cancer. However, not all tumor markers are specific to one kind of cancer. Therefore, tumor markers are often used with additional tests to diagnose cancer. One of the efficient ways to measure tumor markers is using chemiluminescence immunoassay (CLIA). CLIA can be performed on automated analyzers that can process multiple samples and parameters simultaneously, reducing the workload and human error in the laboratory.

Furthermore, adopting CLIA for tumor marker testing is a forward-thinking move toward achieving accuracy and efficiency in cancer diagnosis. This advanced method offers high specificity – crucial in detecting different types of cancers. The automation also decreases the likelihood of manual errors during testing, providing more reliable results. Thus, using CLIA for tumor marker testing is essential in providing support for cancer diagnosis.

One of the advanced chemiluminescence immunoassay analyzers in the market is the Automatic Chemiluminescence Immunoassay Analyzer iA1000 from Artron Laboratories. The iA1000 is a fully automated, compact, and user-friendly analyzer that can perform up to 120 tests per hour with high precision and accuracy. The iA1000 uses a disposable plastic cuvette with 200 automatic loading and unloading pieces in one batch. It also has a built-in quality control system, a touchscreen interface, and a barcode reader for easy operation and data management.

The iA1000 can detect a wide range of tumor markers, including but not limited to:

  • CYFRA21-1: a marker for lung cancer, especially non-small cell lung cancer, along with carcinoembryonic antigen and squamous cell carcinoma.
  • NSE: a marker for neuroendocrine tumors, such as small cell lung cancer and neuroblastoma.
  • AFP: is a marker for liver, ovary, or testicle cancer.
  • CEA: a marker for colorectal cancer and several other cancers.
  • SCCA: a marker for squamous cell carcinoma, such as cervical, head, neck, and lung cancer.
The iA1000 can also detect tumor markers in CA125, CA15-3, CA19-9, CA72-4, HE4, PIVKA II, ProGRP, CA50, CA242, and LN. Contact our representatives at to learn more about our comprehensive test menu.
The Role of Automatic Chemiluminescence Immunoassay Analyzer iA1000 in Tumor Testing

February 4th is World Cancer Day, an international awareness day to promote cancer prevention and detection. This year, the theme of World Cancer Day is “Close the Care Gap”. Artron Laboratories is proud to provide healthcare professionals worldwide with the iA1000 analyzer. By using the iA1000, you can get accurate and timely information on the tumor markers of your patients, which can help you make better decisions on diagnosis, treatment, and follow-up, facilitating the closure of gaps in care.

Garcia-Valdecasas Gayo, S., Ruiz-Alvarez, M., Gonzalez-Gay, D., Ramos-Corral, R., Marquez-Lietor, E., Del Amo, N., Plata, M., Guillén-Santos, R., Arribas, I. & Cava-Valenciano, F. (2020). CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, 1(4), 20200005.
Neuron-specific enolase (NSE). (n.d.). Stanford Health Care.
Alpha-fetoprotein (AFP). (n.d.). Stanford Health Care. 
[Carcinoembryonic antigen (CEA). (n.d.). Stanford Health Care.
SCCA - Overview: Squamous cell carcinoma antigen, serum. (n.d.). 
Campaign theme I World Cancer Day. (n.d.).

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top